These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735 [TBL] [Abstract][Full Text] [Related]
3. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540 [TBL] [Abstract][Full Text] [Related]
4. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study. Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225 [TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Amaral T; Tampouri I; Eigentler T; Keim U; Klumpp B; Heinrich V; Zips D; Paulsen F; Gepfner-Tuma I; Skardelly M; Tatagiba M; Tabatabai G; Garbe C; Forschner A Immunotherapy; 2019 Mar; 11(4):297-309. PubMed ID: 30606066 [TBL] [Abstract][Full Text] [Related]
8. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835 [TBL] [Abstract][Full Text] [Related]
9. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy. Carron R; Gaudy-Marqueste C; Amatore F; Padovani L; Malissen N; Balossier A; Loundou A; Bonnet N; Muracciole X; Régis JM; Grob JJ Eur J Cancer; 2020 Aug; 135():52-61. PubMed ID: 32535348 [TBL] [Abstract][Full Text] [Related]
11. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317 [TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757 [TBL] [Abstract][Full Text] [Related]
13. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745 [TBL] [Abstract][Full Text] [Related]
15. Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases. Grätz V; Langan EA; Neumann A; Zillikens D; Terheyden P Melanoma Res; 2019 Oct; 29(5):516-521. PubMed ID: 30870272 [TBL] [Abstract][Full Text] [Related]
16. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Qian JM; Yu JB; Kluger HM; Chiang VL Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122 [TBL] [Abstract][Full Text] [Related]